NewAmsterdam Pharma Company N.V. NAMS
Regular-session close
After hours · Nov 19, 5:01 PM ET
- YTD
- -44.38%
- 1 year
- -49.48%
5D -0.28 (-1.41%)
- Market cap
- 2.34B
- Revenue (ttm)
- 25.94M
- EPS (ttm)
- -1.69
- Shares out
- 119.93M
- Forward P/E
- -9.40
- YTD return
- -44.38%
- 1-year return
- -49.48%
- 50-day average
- 21.22
- 200-day average
- 28.97
- Enterprise value
- 1.74B
- Volume
- 1.98M
- Avg volume
- 1.63M
- Open
- 20.14
- Previous close
- 19.74
- Day's range
- 19.30 – 20.36
- 52-week range
- 17.90 – 42.21
- Beta
- 0.14
- Analysts
- Strong Buy
- Price target
- 50.73 (+160.0%)
- Earnings date
- Feb 17, 2027
Key statistics
- Price / sales
- 90.21
- Price / book
- 3.71
- Revenue growth
- 5406.90%
- Free cash flow
- -98.63M
- Total cash
- 628.24M
- Total debt
- 76.00K
- Return on equity
- -30.16%
- Short % of float
- 11.72%
Fundamental scorecard
4 of 25 checks passed on NAMS’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 37.41
- Target (mean)
- 50.73
- Target (high)
- 60.04
- Strong buy3
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 17, 2027
Expected Feb 17, 2027. Consensus EPS estimate -0.42046.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 17, 2027 | Dec 30, 2026 | -0.44 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.47179 | -0.14 | +0.33 | +70.33% |
| Aug 5, 2026 | Jun 30, 2026 | -0.48191 | -0.52 | -0.04 | -7.90% |
| May 7, 2026 | Mar 31, 2026 | -0.46 | -0.40 | +0.06 | +13.04% |
| Feb 18, 2026 | Dec 31, 2025 | -0.4342 | -0.63 | -0.20 | -45.09% |
| Nov 5, 2025 | Sep 30, 2025 | -0.38 | -0.61 | -0.23 | -60.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Nov 5, 2026 | Needham | main | Buy | Buy |
| Oct 5, 2026 | RBC Capital | main | Outperform | Outperform |
| Sep 8, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 6, 2026 | RBC Capital | main | Outperform | Outperform |
| Jun 30, 2026 | RBC Capital | main | Outperform | Outperform |
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- Website
- newamsterdampharma.com
News
Your note
Sign in to keep a note on NAMS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AUDET JULIETTE BERANGERE | Officer | Stock Award(Grant) | Jan 6, 2025 | 15,104 |
| DAVIDSON MICHAEL H | Chief Executive Officer | Purchase | Sep 13, 2026 | 1,078,640 |
| FORGROWTH NAP B.V. | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 29, 2024 | 0 |
| JONES WILLIAM A JR | Officer | Stock Award(Grant) | Jan 6, 2025 | 43,000 |
| KASTELEIN JOHANNES JACOB PIETER | Officer and Director | Sale | Aug 23, 2026 | 0 |
| KLING DOUGLAS F | Chief Operating Officer | Sale | Jul 15, 2025 | 44,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 15.83% | 18,988,902 | 370.47M | Sep 29, 2026 |
| Capital World Investors | 10.74% | 12,881,484 | 251.32M | Sep 29, 2026 |
| FMR, LLC | 10.10% | 12,116,744 | 236.40M | Sep 29, 2026 |
| RA Capital Management, L.P. | 7.96% | 9,550,191 | 186.32M | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 7.48% | 8,972,293 | 175.05M | Sep 29, 2026 |
| FCPM III Services B.V. | 7.08% | 8,490,353 | 165.65M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 7.97% | 9,562,970 | 186.57M | Sep 29, 2026 |
| Fidelity Contrafund | 1.92% | 2,304,826 | 44.97M | Sep 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 1.84% | 2,204,738 | 43.01M | Sep 29, 2026 |
| New Economy Fund | 1.04% | 1,246,093 | 24.31M | Sep 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 0.97% | 1,164,951 | 22.73M | Sep 29, 2026 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 0.85% | 1,020,000 | 19.90M | Sep 29, 2026 |
